Barinthus Biotherapeutics (BRNS) Enterprise Value (2020 - 2026)
Barinthus Biotherapeutics' (BRNS) quarterly Enterprise Value came in at -$67.1 million in Q1 2026, up 33.21% YoY from -$50.4 million in Q1 2025, and up 6.49% on a QoQ basis from -$71.8 million in Q4 2025.
Barinthus Biotherapeutics (BRNS) Enterprise Value (2020 - 2026) Analysis & Trends
Barinthus Biotherapeutics (BRNS) has 7 years of Enterprise Value data on file, last reported at -$67.1 million in Q1 2026.
- Quarterly Enterprise Value rose 33.21% year-over-year to -$67.1 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was -$67.1 million (up 33.21% YoY) and the FY2025 annual result came in at -$71.8 million, up 36.09% from the prior year.
- Enterprise Value climbed to -$67.1 million in Q1 2026, from -$71.8 million in the prior quarter.
- In the past five years, Enterprise Value ranged from a high of -$67.1 million in Q1 2026 to a low of -$200.2 million in Q1 2022.
- A 5-year average of -$136.5 million and a median of -$129.8 million in 2024 frame the typical range for Enterprise Value.
- Annual changes were most pronounced in 2022 — Enterprise Value slumped 1123.18% — and 2025, when it soared 36.09%.
- Tracing BRNS's Enterprise Value over 5 years: stood at -$194.1 million in 2022, then increased by 26.9% to -$141.9 million in 2023, then grew by 20.85% to -$112.3 million in 2024, then surged by 36.09% to -$71.8 million in 2025, then rose by 6.49% to -$67.1 million in 2026.
- The last three Enterprise Value figures came in at -$67.1 million (Q1 2026), -$71.8 million (Q4 2025), and -$75.6 million (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Enterprise Value (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.29 Bn | 131.44 Bn | 2.84 Bn | -7.85 Bn |
| 2 | Regeneron Pharmaceuticals | 86.31 Bn | 78.32 Bn | 3.93 Bn | -7.99 Bn |
| 3 | Argenx Se | 64.95 Bn | 59.77 Bn | 1.37 Bn | -5.18 Bn |
| 4 | Moderna | 59.49 Bn | 54.36 Bn | 52.00 Mn | -5.14 Bn |
| 5 | BeOne Medicines | 42.02 Bn | 36.92 Bn | 1.53 Bn | -5.10 Bn |
| 6 | Alnylam Pharmaceuticals | 30.79 Bn | 27.48 Bn | 992.69 Mn | -3.31 Bn |
| 7 | BioNTech SE | 28.26 Bn | 9.87 Bn | 668.28 Mn | -18.39 Bn |
| 8 | Insmed | 27.30 Bn | 26.14 Bn | 358.27 Mn | -1.16 Bn |
| 9 | Royalty Pharma | 27.10 Bn | 26.26 Bn | - | 2.12 Bn |
| 10 | Barinthus Biotherapeutics | 25.73 Mn | 25.73 Mn | - | -59.57 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -59.57 Mn |
| Mar 31, 2026 | -67.11 Mn |
| Dec 31, 2025 | -71.77 Mn |
| Sep 30, 2025 | -75.58 Mn |
| Jun 30, 2025 | -87.68 Mn |
| Mar 31, 2025 | -100.48 Mn |
| Dec 31, 2024 | -112.29 Mn |
| Sep 30, 2024 | -105.94 Mn |
| Jun 30, 2024 | -117.63 Mn |
| Mar 31, 2024 | -129.82 Mn |
| Dec 31, 2023 | -141.88 Mn |
| Sep 30, 2023 | -160.10 Mn |
| Jun 30, 2023 | -172.78 Mn |
| Mar 31, 2023 | -191.06 Mn |
| Dec 31, 2022 | -194.08 Mn |
| Sep 30, 2022 | -199.79 Mn |
| Jun 30, 2022 | -191.96 Mn |
| Mar 31, 2022 | -200.20 Mn |
| Dec 31, 2021 | -213.62 Mn |
| Sep 30, 2021 | -233.38 Mn |